In addition, in terms of molecular targeted therapy prediction, our results show that the increased expression of AQP2 and CLDN19 is associated with the sensitivity to imiquimod, an imidazoline derivative commonly used to treat genital warts. The gene discussed is AQP2; the disease is anogenital human papillomavirus infection.